SPY423.13+2.27 0.54%
DIA339.50+0.72 0.21%
IXIC14,253.27+111.79 0.79%

BRIEF-Exelixis Says Notified By Ipsen Pharma That Ipsen Exercised Its Option To Collaborate With Co In Phase 3 Cosmic-311 Pivotal Trial

05/11/2021 18:53
BRIEF-Exelixis Says Notified By Ipsen Pharma That Ipsen Exercised Its Option To Collaborate With Co In Phase 3 Cosmic-311 Pivotal Trial

- Exelixis Inc EXEL.O:

  • EXELIXIS INC - ON MAY 7 NOTIFIED BY IPSEN PHARMA SAS THAT IPSEN EXERCISED ITS OPTION TO COLLABORATE WITH CO IN PHASE 3 COSMIC-311 PIVOTAL TRIAL

  • EXELIXIS INC - UNDER TERMS OF AGREEMENT, IPSEN IS NOW RESPONSIBLE FOR 35% OF GLOBAL DEVELOPMENT COSTS OF COSMIC-311

  • EXELIXIS - THROUGH QUARTER ENDED APRIL 2, 2021, CO ESTIMATES IPSEN'S SHARE OF COSMIC-311 DEVELOPMENT COSTS, PLUS ADDITIONAL PAYMENT, TO BE ABOUT $40 MILLION

  • EXELIXIS INC - CURRENTLY EVALUATING AMOUNT AND TIMING OF REVENUE RECOGNITION FOR COSMIC-311 DEVELOPMENT COST REIMBURSEMENTS

Source: (https://bit.ly/3uRYzGY)

Further company coverage: EXEL.O


(([email protected];))